Ryan Meuth

March 22, 2021 | New York Law Journal

Recent Federal Circuit precedent has given some hope that, through the use of artfully‑drafted claim language, diagnostic tests may still be eligible for patenting. And in view of the central importance of diagnostic testing to the present COVID-19 crisis, the policy considerations that underlie strengthening innovation incentives in the diagnostic space have become more compelling and more urgent.

By Melanie Rupert and Ryan Meuth

8 minute read